Abstract:Abstract Hepatocellular carcinoma (HCC) is a common type of cancer globally and is associated with a poor prognosis due to its high recurrence rate and resistance to treatment. Solid evidence showed the existence of cancer stem cells (CSCs) that are crucial for therapeutic resistance. However, there are only a few kinase inhibitors that have been found to specifically target liver T-ICs for the HCC treatment. To understand the regulatory mechanism of liver CSCs, we employed RNA-Seq analysis to compare the gene expression profiles, with a particular focus on protein kinases, between (1) sorted CD133+ liver CSCs and CD133- differentiated cells extracted from two HCC cell lines (Huh7 and PLC8024), as well as cultured hepatospheres and adherent differentiated cells of HCC cell line PLC/PRF/5. Our analysis identified Serine/Threonine kinase 39 (STK39) as a commonly up-regulated protein kinase in both CD133+ liver CSCs and CSC-enriched hepatospheres. Based on our analysis of the TCGA data, a positive correlation has consistently been observed between STK39 mRNA expression and the expression of liver CSC markers, including CD24, CD133, and CD47. Utilizing publicly available transcriptome datasets from the NCBI Gene Expression Omnibus (GEO), including GSE14520 and GSE25097, we found that overexpression of STK39 is detected in HCC tumor tissues (p<0.001) and is significantly associated with poorer overall survival and disease-free survival. Through the use of lentiviral based overexpression and knockdown approaches, we have demonstrated the role of STK39 in regulating liver CSC properties, including self-renewal, tumorigenicity, cell invasiveness, and the expression of liver CSC markers. STK39 expression was found to be significantly elevated in in HCC cells that were resistant to both sorafenib and lenvatinib, and its inhibition resulted in increased sensitivity of HCC cells to these treatments. To identify the downstream target of STK39 for regulation of cancer stemness, tandem affinity purification coupled with mass spectrometry was employed. The analysis led to the identification of PARP1 as a novel protein binding partner of STK39. Upon suppression of STK39 in HCC cells, it was observed that the phosphorylation of PARP1 at Threonine 368 (T368) was significantly inhibited, indicating its role as a downstream effector of STK39-mediated liver CSC functions. Interestingly, STK39-mediated PARP1 phosphorylation led to development of resistance to PARP1 inhibitor, rucaparib. Additionally, STK39 plays a critical role in regulating PARP1-mediated chromatin decondensation, which enables it to open chromatin structure at the promoter regions of SOX2/OCT4. In summary, treatment of molecular targeted drugs including rucaparib and lenvatinib with STK39 inhibitor may be a potential therapeutic strategy for treatment of this deadly disease. Citation Format: Carmen Oi Ning Leung, Terence Kin-Wah Lee. Identification of serine/threonine kinase 39 (STK39) as a driver for multidrug resistance in hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5431.

Calcium-Binding Protein 39 Promotes Hepatocellular Carcinoma Growth and Metastasis by Activating Extracellular Signal-Regulated Kinase Signaling Pathway

Bioinformatics Prediction and Experimental Verification Identify CAB39L As a Diagnostic and Prognostic Biomarker of Kidney Renal Clear Cell Carcinoma.

CAB39 modulates epithelial-mesenchymal transition through NF-κB signaling activation, enhancing invasion, and metastasis in bladder cancer

DDX39 Promotes Hepatocellular Carcinoma Growth and Metastasis Through Activating Wnt/β-catenin Pathway

STK39 is a Novel Kinase Contributing to the Progression of Hepatocellular Carcinoma by the PLK1/ERK Signaling Pathway.

CD44 Potentiates Hepatocellular Carcinoma Migration and Extrahepatic Metastases Via the AKT/ERK Signaling CXCR4 Axis.

Upregulated Calcium‐binding Tyrosine Phosphorylation‐regulated Protein‐a/b Regulates Cell Proliferation and Apoptosis and Predicts Poor Prognosis in Hepatocellular Carcinoma

B-Cell Receptor-Associated Protein 31 Promotes Metastasis Via AKT/β-Catenin/Snail Pathway in Hepatocellular Carcinoma

DDX39B facilitates the malignant progression of hepatocellular carcinoma via activation of SREBP1-mediated de novo lipid synthesis

ARHGEF39 targeted by E2F1 fosters hepatocellular carcinoma metastasis by mediating fatty acid metabolism

Downregulation of CYP39A1 Serves As a Novel Biomarker in Hepatocellular Carcinoma with Worse Clinical Outcome

Up-regulated Expression of Phospholipase C, β1 is Associated with Tumor Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma

STK39 Enhances the Progression of Cholangiocarcinoma Via PI3K/AKT Pathway

Cyclin-dependent Kinase 19 Upregulation Correlates with an Unfavorable Prognosis in Hepatocellular Carcinoma

T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1

Cx32 exerts anti-apoptotic and pro-tumor effects via the epidermal growth factor receptor pathway in hepatocellular carcinoma

Expression of Rho Guanine Nucleotide Exchange Factor 39 (ARHGEF39) and Its Prognostic Significance in Hepatocellular Carcinoma.

CKLF1 Enhances Inflammation-mediated Carcinogenesis and Prevents Doxorubicin-induced Apoptosis via IL-6/STAT3 Signaling in HCC.

CCDC178 Promotes Hepatocellular Carcinoma Metastasis Through Modulation of Anoikis

Overexpression of CD39 in Hepatocellular Carcinoma is an Independent Indicator of Poor Outcome after Radical Resection.

Abstract 5431: Identification of serine/threonine kinase 39 (STK39) as a driver for multidrug resistance in hepatocellular carcinoma